<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aprepitant: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aprepitant: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aprepitant: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11166" href="/d/html/11166.html" rel="external">see "Aprepitant: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="17055" href="/d/html/17055.html" rel="external">see "Aprepitant: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F136348"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aponvie;</li>
<li>Cinvanti;</li>
<li>Emend;</li>
<li>Emend Tri-Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865962"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Emend;</li>
<li>Emend Tri-Pack</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F136367"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiemetic;</li>
<li>
                        Substance P/Neurokinin 1 Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F136351"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is for aprepitant (Emend oral, Aponvie IV, and Cinvanti IV); refer to the fosaprepitant monograph for Emend IV dosing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Manufacturer's labeling:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of <b>acute and delayed</b> nausea/vomiting associated with <b>highly-emetogenic</b> chemotherapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (single-dose aprepitant regimen):</b>
<b>Cinvanti:</b> 130 mg ~30 minutes prior to chemotherapy on day 1 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and oral dexamethasone on days 1 to 4).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Capsules: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and dexamethasone on days 1 to 4).</p>
<p style="text-indent:-2em;margin-left:10em;">Suspension: Adults unable to swallow capsules: 3 mg/kg (maximum: 125 mg/dose) 1 hour prior to chemotherapy on day 1, followed by 2 mg/kg (maximum: 80 mg/dose) once daily on days 2 and 3 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and dexamethasone on days 1 to 4).</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of nausea/vomiting associated with <b>moderately emetogenic</b> chemotherapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (3-day aprepitant regimen):</b>
<b>Cinvanti:</b> 100 mg ~30 minutes prior to chemotherapy on day 1 (in combination with oral aprepitant 80 mg on days 2 and 3, a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and dexamethasone on day 1).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Capsules: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic and dexamethasone on day 1).</p>
<p style="text-indent:-2em;margin-left:10em;">Suspension: Adults unable to swallow capsules: 3 mg/kg (maximum: 125 mg/dose) 1 hour prior to chemotherapy on day 1, followed by 2 mg/kg (maximum: 80 mg/dose) once daily on days 2 and 3 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic and dexamethasone on day 1).</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of <b>delayed</b> nausea/vomiting associated with <b>moderately emetogenic</b> chemotherapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (single-dose aprepitant regimen):</b>
<b>Cinvanti:</b> 130 mg ~30 minutes prior to chemotherapy on day 1 (in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and dexamethasone on day 1).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Guideline recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of nausea/vomiting associated with highly emetogenic chemotherapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cisplatin and other highly emetogenic single agents</i>: Administer aprepitant in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1, dexamethasone on days 1 to 4, and olanzapine on days 1 to 4.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (Cinvanti):</b> 130 mg on day 1 only (single-dose aprepitant regimen).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 125 mg prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Anthracycline in combination with cyclophosphamide (AC) </i>
<i>regimens</i>: Administer aprepitant in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1, dexamethasone on day 1, and olanzapine on days 1 to 4.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (Cinvanti):</b> 130 mg on day 1 only (single-dose aprepitant regimen).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 125 mg prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Multiday (4</i>
<i>- or 5-day) cisplatin regimens</i>: Administer aprepitant in combination with a 5-HT<sub>3</sub> antagonist antiemetic and dexamethasone.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (Cinvanti):</b> 130 mg on day 1 only (single-dose aprepitant regimen).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 125 mg prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Carboplatin AUC ≥4 doses</i>: Administer aprepitant in combination with a 5-HT<sub>3</sub> antagonist antiemetic on day 1 and dexamethasone on day 1.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (Cinvanti), Oral:</b> 100 mg IV, followed by 80 mg orally on days 2 and 3 <b>or</b> 125 mg orally on day 1, followed by 80 mg orally on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>High-dose chemotherapy </i>
<i>with stem-cell or bone marrow transplant</i>: Administer aprepitant in combination with a 5-HT<sub>3</sub> antagonist antiemetic and dexamethasone, with or without olanzapine.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV (Cinvanti):</b> 130 mg on day 1 only (single-dose aprepitant regimen).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 125 mg prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Aponvie: <b>IV:</b> 32 mg prior to anesthesia induction.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules (generic): <b>Oral:</b> 40 mg within 3 hours prior to anesthesia induction. <b>Note:</b> The postoperative nausea and vomiting indication was removed from the Emend capsule US prescribing information; however, it remains in the labeling for generic capsule products.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990970"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage kidney disease undergoing dialysis: No dosage adjustment necessary. Hemodialysis conducted 4 or 48 hours after dosing had no significant impact on aprepitant pharmacokinetics (a negligible amount of an aprepitant dose is recovered in the dialysate).</p></div>
<div class="block doha drugH1Div" id="F50988338"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment (Child-Pugh class C): Use with caution; no data available; may require additional monitoring for adverse reactions. </p></div>
<div class="block dot drugH1Div" id="F56772703"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions: Discontinue aprepitant infusion and manage appropriately. Do not reinitiate.</p></div>
<div class="block doe drugH1Div" id="F136352"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F26419175"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="17055" href="/d/html/17055.html" rel="external">see "Aprepitant: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Concentration of oral suspension may vary (commercially available or extemporaneous compounded); use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2791f691-127b-40fb-90cf-ead84edbdbb6">Chemotherapy-induced nausea and vomiting, prevention; highly and moderately emetogenic chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting (CINV), prevention; highly and moderately emetogenic chemotherapy: Note:</b> Use in combination with 5-HT<sub>3</sub> antagonist antiemetic with or without dexamethasone depending upon patient age, chemotherapy emetogenic potential, and drug-interaction profile (refer to specific protocols or guidelines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28453189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28453189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;12 years weighing 6 to &lt;30 kg: Oral: Oral suspension: 3 mg/kg 1 hour prior to chemotherapy on day 1, then 2 mg/kg/dose once daily on days 2 and 3. <b>Note:</b> For commercially available product (25 mg/mL), may round dose to nearest 2.5 mg (0.1 mL) for doses ≤25 mg or to the nearest 5 mg (0.2 mL) for doses &gt;25 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years weighing ≥30 kg, Children ≥12 years, and Adolescents: Oral: Capsules, Oral suspension: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7fc4235-c695-4f6f-8b85-6a2ed65e8502">Cyclic vomiting syndrome, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, prophylaxis</b>
<b>:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prophylaxis is recommended for patients experiencing frequent symptoms (eg, monthly) or severe symptoms (eg, requiring hospitalization, lasting &gt;2 days, resulting in significant school/work absences) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469','lexi-content-ref-18728540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;40 kg: Oral: 40 mg twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">40 to 60 kg: Oral: 80 mg twice weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: Oral: 125 mg twice weekly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a931b1a-3be3-44de-aef4-42c486dea268">Cyclic vomiting syndrome, abortive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, abortive therapy: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer during prodromal phase at least 30 minutes prior to onset of vomiting and continue for a total of 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24898244','lexi-content-ref-30076469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24898244','lexi-content-ref-30076469'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;15 kg: Oral: 80 mg on day 1 followed by 40 mg on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 20 kg: Oral: 80 mg on day 1 followed by 80 mg on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 kg: Oral: 125 mg on day 1 followed by 80 mg on days 2 and 3.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064904"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild, moderate, or severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis-dependent end-stage renal disease (ESRD): No dosage adjustment necessary. Aprepitant is not removed by hemodialysis (&lt;0.2% of a dose is recovered in the dialysate).</p></div>
<div class="block dohp drugH1Div" id="F51064905"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use with caution; no data available; may require additional monitoring for adverse reactions.</p></div>
<div class="block adr drugH1Div" id="F136321"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions may be reported in combination with other antiemetic agents. Reported adverse reactions are for adults with highly emetogenic cancer chemotherapy or moderately emetogenic cancer chemotherapy, unless otherwise noted as reported for postoperative nausea and vomiting (PONV) or in children and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (children and adolescents: 13%; adults: &lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (children and adolescents: 5%; adults: 13% [PONV: 6%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (&lt;3%), hypotension (PONV: 6%), palpitations (&lt;3%), peripheral edema (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;3%), hyperhidrosis (&lt;3%), skin rash (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum sodium (&lt;3%), dehydration (3%), hot flash (&lt;3), hypokalemia (&lt;3%), weight loss (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (6%), constipation (PONV: 8% to 9%), decreased appetite (children and adolescents: 5%; adults: &lt;3%), diarrhea (children and adolescents: 6%; adults: 9%), dysgeusia (&lt;3%), dyspepsia (7%), eructation (&lt;3%), flatulence (&lt;3%), gastritis (&lt;3%), gastroesophageal reflux disease (&lt;3%), hiccups (children and adolescents: 4%; adults: 5%), oral candidiasis (&lt;3%), xerostomia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;3%), febrile neutropenia (&lt;3%), thrombocytopenia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (3%), increased serum alkaline phosphatase (&lt;3%), increased serum aspartate aminotransferase (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (&lt;3%), asthenia (7%), dizziness (children and adolescents: 5%; adults: &lt;3% [PONV: &lt;1%]), headache (children and adolescents: 9%; adults [PONV]: 4%), malaise (&lt;3%), peripheral neuropathy (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children and adolescents: 5%; adults: &lt;3%), dyspnea (&lt;3%), oropharyngeal pain (&lt;3%), pharyngitis (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Urticaria (PONV: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F136334"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to aprepitant or any component of the formulation; concurrent use with pimozide</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Concurrent use with astemizole, cisapride, or terfenadine.</p></div>
<div class="block war drugH1Div" id="F136319"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions, have been reported. Symptoms have included dyspnea, erythema, eye swelling, flushing, hypotension, pruritus, syncope, and wheezing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-drug interactions: A clinically significant decrease in INR or PT may occur with concurrent warfarin therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: For prevention of chemotherapy-induced nausea and vomiting, oral suspension use is not recommended in pediatric patients weighing &lt;6 kg. Generic aprepitant capsules are not approved for use in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aprepitant IV: The IV aprepitant formulations are an emulsion that also contains the excipients alcohol, egg lecithin, soybean oil, and sucrose.</p></div>
<div class="block foc drugH1Div" id="F136328"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend: 40 mg [DSC], 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend Tri-Pack: 80 mg &amp; 125 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 80 mg, 125 mg, 80 mg &amp; 125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aponvie: 32 mg/4.4 mL (4.4 mL) [contains alcohol, usp, egg phospholipids (egg lecithin), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cinvanti: 130 mg/18 mL (18 mL) [contains alcohol, usp, egg phospholipids (egg lecithin), soybean oil]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Miscellaneous, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg &amp; 125 mg (3 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend: 125 mg/5 mL (1 ea)</p></div>
<div class="block geq drugH1Div" id="F136315"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F3422188"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Aprepitant Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $109.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $203.76 - $203.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $318.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Emend Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $262.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Emend Tri-Pack Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 &amp; 125 mg (per each): $309.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Aponvie Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32MG/4.4ML (per mL): $15.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Cinvanti Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">130 mg/18 mL (per mL): $28.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Misc</b> (Aprepitant Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 &amp; 125 mg (per each): $240.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Emend Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per each): $410.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865963"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend: 80 mg, 125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Miscellaneous, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend Tri-Pack: 80 mg &amp; 125 mg (3 ea)</p></div>
<div class="block adm drugH1Div" id="F136331"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administration information is for aprepitant IV (Aponvie, Cinvanti); refer to fosaprepitant IV (Emend IV) monograph for fosaprepitant administration information.</p>
<p style="text-indent:-2em;margin-left:4em;">Aponvie: IV injection: Inject over 30 seconds prior to anesthesia induction. Flush infusion line with NS before and after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Cinvanti:</p>
<p style="text-indent:-2em;margin-left:6em;">IV injection: Inject over 2 minutes approximately one-half hour (30 minutes) prior to chemotherapy. Flush infusion line with NS before and after administration.</p>
<p style="text-indent:-2em;margin-left:6em;">IV infusion: Infuse over 30 minutes approximately one-half hour (30 minutes) prior to chemotherapy. Use only non-DEHP tubing for administration of the IV infusion (not necessary if administering as an IV push).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of chemotherapy-induced nausea/vomiting: Administer with or without food. First dose should be given 1 hour prior to chemotherapy; subsequent doses should be given 1 hour prior to chemotherapy or in the morning (if no chemotherapy is administered on days 2 and 3). Swallow capsules whole.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral suspension: Dose should be prepared by a health care provider and dispensed to patient or caregiver in an oral dispenser. Administer by placing the dispenser in the patient's mouth along the inner cheek and slowly dispensing the medicine.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of postoperative nausea/vomiting (oral): Administer within 3 hours prior to induction; follow health care provider instructions about food/drink restrictions prior to surgery. Swallow capsules whole.</p></div>
<div class="block admp drugH1Div" id="F52612257"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention of chemotherapy-induced nausea/vomiting: May be administered without regard to food. The first dose should be administered 1 hour prior to chemotherapy; subsequent dose should be given1 hour prior to chemotherapy or in the morning (ie, if no chemotherapy is administered on days 2 and 3).</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Swallow whole</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Remove cap from oral syringe. Slowly administer suspension along the inner cheek.</p></div>
<div class="block use drugH1Div" id="F136330"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV (Aponvie):</b>
<b>Postoperative nausea and vomiting:</b> Prevention of postoperative nausea and vomiting in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV (Cinvanti):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of chemotherapy-induced nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of <b>highly</b> emetogenic chemotherapy, including high-dose cisplatin, as single-dose aprepitant regimen (in combination with other antiemetics) in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of delayed nausea and vomiting associated with initial and repeat courses of <b>moderately</b> emetogenic chemotherapy as a single-dose aprepitant regimen (in combination with other antiemetics) in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of nausea and vomiting associated with initial and repeat courses of <b>moderately</b> emetogenic chemotherapy as a 3-day aprepitant regimen (in combination with other antiemetics) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral (Emend oral): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention of chemotherapy-induced nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of <b>highly</b> emetogenic chemotherapy, including high-dose cisplatin (in combination with other antiemetics) in patients ≥12 years of age (capsules) and in patients ≥6 months of age (oral suspension).</p>
<p style="text-indent:-2em;margin-left:6em;">Prevention of nausea and vomiting associated with initial and repeat courses of <b>moderately</b> emetogenic chemotherapy (in combination with other antiemetics) in patients ≥12 years (capsules) and in patients ≥6 months (oral suspension).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Postoperative nausea and vomiting (generic capsules):</b> Prevention of postoperative nausea and vomiting (PONV) in adults. <b>Note:</b> The PONV indication was removed from the Emend capsule US prescribing information (in September 2019); however, it remains in the labeling for generic aprepitant capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Aprepitant has not been studied for the management of existing nausea and vomiting. Chronic, continuous administration (oral aprepitant) is not recommended (has not been studied and chronic use may alter aprepitant's drug interaction profile).</p></div>
<div class="block mst drugH1Div" id="F5656106"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aprepitant may be confused with fosaprepitant, fosnetupitant, netupitant, rolapitant</p>
<p style="text-indent:-2em;margin-left:4em;">Aprepitant IV (Cinvanti) may be confused with fosaprepitant IV (Emend for injection)</p>
<p style="text-indent:-2em;margin-left:4em;">Emend (aprepitant) oral capsule/suspension formulations may be confused with Emend for injection (fosaprepitant)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F136361"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (moderate); <b>Induces</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F136323"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride.  Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Aprepitant.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Aprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Aprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Aprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): Aprepitant may increase the serum concentration of DexAMETHasone (Systemic).  Management: Reduce dexamethasone dose 50% with aprepitant. Aprepitant labeling incorporates this recommendation into the dose provided for dexamethasone; further reduction is not necessary. No dose adjustment may be needed with single, low-dose aprepitant for PONV.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib.  Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Aprepitant may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Avoid use of fexinidazole and moderate CYP3A4 inhibitors when possible. If combined, monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Aprepitant may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with aprepitant, and to continue back-up contraception for 28 days after discontinuing aprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: Aprepitant may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk for ifosfamide induced encephalopathy may be increased. Aprepitant may increase serum concentrations of the active metabolite(s) of Ifosfamide. Specifically, concentrations of the active and toxic metabolites of ifosfamide may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib.  Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: Aprepitant may increase the serum concentration of Lonafarnib. Lonafarnib may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a moderate CYP3A4 inhibitor. For those stable on mavacamten who are initiating a moderate CYP3A4 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methadone.  Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: Aprepitant may increase the serum concentration of MethylPREDNISolone.  Management: Decrease oral methylprednisolone dose by 50%, and decrease intravenous methylprednisolone dose by 25%, with aprepitant. No dose adjustment is required when used with only a single 40 mg oral dose or 32 mg injectable dose of aprepitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib.  Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Aprepitant may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein.  For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Aprepitant may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F136346"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Aprepitant serum concentration may be increased when taken with grapefruit juice. Management: Avoid concurrent use. </p></div>
<div class="block rep_considerations drugH1Div" id="F49095562"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Efficacy of hormonal contraceptive may be reduced during treatment and for 1 month following the last aprepitant dose; alternative or backup contraception (eg, condoms, spermicides) should be used during treatment with aprepitant and for 1 month following the last aprepitant dose.</p></div>
<div class="block pri drugH1Div" id="F136335"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The injection formulation contains ethanol; avoid use in patients who are pregnant.</p></div>
<div class="block brc drugH1Div" id="F16132204"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if aprepitant is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The injection formulation contains ethanol.</p></div>
<div class="block mop drugH1Div" id="F44941664"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">In patients receiving concurrent warfarin, monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration. Monitor patients with severe hepatic impairment for adverse reactions. Monitor for signs/symptoms of hypersensitivity reaction.</p></div>
<div class="block pha drugH1Div" id="F136318"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aprepitant prevents acute and delayed vomiting by inhibiting the substance P/neurokinin 1 (NK<sub>1</sub>) receptor; augments the antiemetic activity of 5-HT<sub>3</sub> receptor antagonists and corticosteroids to inhibit acute and delayed phases of chemotherapy-induced emesis.</p></div>
<div class="block phk drugH1Div" id="F136333"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV, Oral: ~70 L; crosses the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: IV: &gt;99%; Oral: &gt;95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 metabolites (weakly active)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~60% to 65%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: IV, Oral: ~9 to 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Pediatric: Capsule: ~4 hours; Suspension ~6 hours; Adults: 40 mg: ~3 hours; 125 mg followed by 80 mg for 2 days: ~4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily via metabolism</p></div>
<div class="block phksp drugH1Div" id="F51220444"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Kidney impairment: Following a single oral aprepitant 240 mg dose in patients with severe kidney impairment (CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>) and end-stage kidney disease requiring hemodialysis, the AUC of total aprepitant (unbound and protein bound) decreased by 21% and C<sub>max</sub> decreased by 32% compared with healthy subjects. In patients with end-stage kidney disease undergoing hemodialysis, the AUC of total aprepitant decreased by 42% and C<sub>max</sub> decreased by 32%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5498259"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant ratiopharm | Aprepitant sandoz | Emend</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant apotex | Emend</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Emend | Emestop</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz | Aprepitant teva | Emend</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Emend | Ou ke ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Emend | Lemid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant sandoz | Aprepitant teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aprepilor | Aprepitant al | Aprepitant beta | Aprepitant heumann | Aprepitant stada | Aprepitant zentiva | Emend</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant sandoz | Emend</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant stada | Emend</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant arrow | Aprepitant biogaran | Aprepitant cristers | Aprepitant Dci | Aprepitant eg | Aprepitant evolgen | Aprepitant mylan | Aprepitant reddy pharma | Aprepitant sandoz | Aprepitant teva | Aprepitant zentiva | Emend</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant mylan | Aprepitant zentiva | Emend</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Emend | Inepitant</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant pharmacenter | Aprepitant q pharm</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Emend</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amitant | Aprecap | Aprelief | Apretero | Aprifast | Apriset | Apristar | Emetant | Fixpritant</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant accord | Aprepitant teva | Atanto | Emend</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant nk | Emend</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz | Emend</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz | Emend | Iramenol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant Aurobindo | Aprepitant CF | Aprepitant sandoz | Aprepitant teva | Aprepitant Xiromed | Emend</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aprefold | Apreon | Aprep | Aprewin | Aprimark | Apritus | G tant | Nautant | Pitantwel | Repitant</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant sandoz | Aprepitant stada | Aprepitant teva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aponvie | Cinvanti | Emend</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant generis | Aprepitant teva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Emend | Enevom</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant 2care4 | Aprepitant ebb | Aprepitant Medical Valley | Aprepitant stada | Emend</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant teva | Emend</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant stada | Aprepitant teva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Sulatan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aprepitant 125 eurolab | Aprepitant 80 eurolab | Aprepitant combipack eurolab</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Aponvie.1">
<a name="Aponvie.1"></a>Aponvie (aprepitant) [prescribing information]. San Diego, CA: Heron Therapeutics Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aprepitant.1">
<a name="Aprepitant.1"></a>Aprepitant capsules [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinvanti.1">
<a name="Cinvanti.1"></a>Cinvanti (aprepitant) injection [prescribing information]. San Diego, CA: Heron Therapeutics Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cinvanti.2">
<a name="Cinvanti.2"></a>Cinvanti (aprepitant) injectable emulsion for intravenous (IV) use administration via IV push, Heron Therapeutics [data on file, January 2019].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898244">
<a name="24898244"></a>Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. <i>Aliment Pharmacol Ther</i>. 2014;40(3):309-317. doi:10.1111/apt.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/24898244/pubmed" id="24898244" target="_blank">24898244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Emend.1">
<a name="Emend.1"></a>Emend (aprepitant) capsules and oral suspension [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356162">
<a name="24356162"></a>Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting [published corrections appear in <i>Anesth Analg</i>. 2015;120(2):494; <i>Anesth Analg</i>. 2014;118(3):689]. <i>Anesth Analg</i>. 2014;118(1):85-113. doi:10.1213/ANE.0000000000000002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/24356162/pubmed" id="24356162" target="_blank">24356162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25770814">
<a name="25770814"></a>Kang HJ, Loftus S, Taylor A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(4):385-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/25770814/pubmed" id="25770814" target="_blank">25770814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393. doi:10.1097/MPG.0b013e318173ed39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28453189">
<a name="28453189"></a>Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. <i>Pediatr Blood Cancer</i>. 2017;64(10).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aprepitant-drug-information/abstract-text/28453189/pubmed" id="28453189" target="_blank">28453189</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9305 Version 417.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
